FDA issued a Warning Letter to Fresenius Kabi Oncology Limited (Baddi) on 12/18/2017 as a result of this inspection.
483 Fresenius Kabi Oncology Limited (Baddi) Apr 2017

483 Fresenius Kabi Oncology Limited (Baddi) Apr 2017

Robert Barbosa FDA, Jose Melendez FDA$119.00 - Available Now

FDA investigators audited the Fresenius Kabi Oncology Limited (Baddi) - Guru Majra, India facility and issued inspectional observations (via FDA 483) on 14 Apr 2017.

Product details

  • Category: Human Drugs
  • Inspection end: 14 Apr 2017
  • Location: Guru Majra, India
  • FEI: 3006210232
Add To Cart